Multiomic Quantification of the KRAS Mutation Dosage Improves the Preoperative Prediction of Survival and Recurrence in Patients with Pancreatic Ductal Adenocarcinoma

Scientists evaluated the prognostic value of the dosage of the KRAS G12 mutation, a key PDAC variant, and investigated the biological mechanism of the prognosis associated with the dosage of the KRAS G12 mutation.